Archive for the ‘
Pharma Business ’ Category
Monday, March 9th, 2009
So, Merck & Co. and Schering-Plough Corp. have formed a definitive merger agreement under which Merck and Schering-Plough will merge under the name Merck in a deal valued at $23.61 per share, or $41.1 billion. Friend of Med Ad News, Mike Luby, has kindly shared his thoughts on the proposed ...
Posted in
Pharma Business |
No Comments »
Tuesday, February 24th, 2009
Watching the Oscars a night late loses a lot of the drama, but on the plus side, you can fast forward through the musical numbers. This year’s telecast didn’t hold a whole lot of interest for me anyway due to what I found to be a lackluster line up of ...
Posted in
Pharma Business |
No Comments »
Friday, January 30th, 2009
Bill Cooney of MedPoint Communications, another frequent contributor to Med Ad News, has shared with us some of his thoughts on Pfizer's planned acquisition of Wyeth.
The Pfizer/Wyeth deal is not only a milestone on its own merits, but it’s even more important as the opening bell for an historic round ...
Posted in
Pharma Business |
1 Comment »
Monday, January 26th, 2009
Mike Luby, co-founder, TargetRx, is a frequent contributor to Med Ad News. I have always found his perspective, as a long-time industry observer, to be invaluable. I asked him to offer his take on Pfizer’s plan to acquire Wyeth, particularly from a sales and marketing perspective.
Does Wyeth offer any marketing ...
Posted in
Pharma Business |
No Comments »
Monday, January 26th, 2009
So, the numbers are in. CNN reports that Pfizer is planning two waves of job cuts for 2009, first cutting 10% of its 81,900 staff. The second round of cuts will take place after the merger with Wyeth is completed in the third or fourth quarter. This is expected to ...
Posted in
Pharma Business |
No Comments »
Monday, January 26th, 2009
The fourth quarter of 2008 was bleak for Pfizer, which was destined to lose its industry-leading position within the next five years. With the planned acquisition of Wyeth, however, Pfizer should stay on top a while longer.
For the fourth quarter , Pfizer posted reported net income of $266 million, a ...
Posted in
Pharma Business |
No Comments »
Monday, January 26th, 2009
Back in February of 2007, I wrote an article in Med Ad News about the history and potential drawbacks of pharmaceutical megamergers ("For richer or poorer"). This past weekend brought the latest chapter in that saga, with the board of Wyeth accepting a $68 billion cash/stock acquisition offer from Pfizer. ...
Posted in
Pharma Business |
1 Comment »
|
|
